Welcome to our dedicated page for Agenus news (Ticker: AGEN), a resource for investors and traders seeking the latest updates and insights on Agenus stock.
Agenus Inc (AGEN) is a clinical-stage biotechnology company pioneering novel immunotherapies to combat cancer and infectious diseases. This page provides centralized access to official press releases, financial updates, and scientific developments from Agenus, offering stakeholders a reliable resource for tracking the company’s progress.
Investors and researchers will find timely updates on clinical trial milestones, regulatory filings, and strategic partnerships, alongside analyses of AGEN’s proprietary platforms like Retrocyte Display™ antibody technology. The curated news collection enables efficient monitoring of the company’s immuno-oncology pipeline and manufacturing advancements through its integrated cGMP facilities.
Key categories include earnings reports, therapy development updates, licensing agreements, and peer-reviewed research highlights. Bookmark this page to stay informed about AGEN’s innovations in checkpoint modulators, cell therapies, and vaccine adjuvants without navigating multiple sources.
Agenus (Nasdaq: AGEN) announced three upcoming presentations at the 2025 ASCO Annual Meeting in Chicago (May 30 - June 3). The presentations include new translational data on botensilimab and balstilimab (BOT/BAL) in colorectal cancer and two trials-in-progress studies.
The first presentation focuses on T-cell dynamics monitoring in mismatch repair-proficient/microsatellite stable metastatic colorectal cancer. The other two presentations detail ongoing clinical studies of botensilimab-based combinations in advanced pancreatic cancer: one examining botensilimab with AGEN1423 (anti-CD73-TGFβ-trap bifunctional antibody), and another investigating a combination therapy including botensilimab, balstilimab, nab-paclitaxel, gemcitabine, cisplatin, chloroquine, and celecoxib.
Agenus (Nasdaq: AGEN) has announced two upcoming presentations at the American Association for Cancer Research (AACR) Annual Meeting in Chicago (April 25-30, 2025), highlighting their neoadjuvant immunotherapy program with botensilimab and balstilimab (BOT/BAL).
The presentations include:
- An oral presentation of initial results from the NEOASIS trial studying BOT/BAL in MMR proficient and deficient early-stage cancers, presented by Dr. Myriam Chalabi from Netherlands Cancer Institute on April 28, 2025
- A poster presentation featuring new data from the Phase 1 study of BOT/BAL in treatment-refractory hepatocellular carcinoma (HCC), presented by Dr. Anthony El-Khoueiry from USC Norris Comprehensive Cancer Center on April 29, 2025
These presentations build upon previous BOT/BAL data from two independent studies (UNICORN and NEST) in colorectal cancer presented earlier at ASCO-GI.
Agenus (NASDAQ: AGEN) has released findings from its national Colorectal Cancer in Focus survey, revealing critical gaps in current treatment options. The survey, conducted from October to December 2024, gathered insights from patients and healthcare providers (HCPs) about colorectal cancer (CRC) care.
Key findings show that over 50% of HCPs reported increased CRC diagnoses in adults under 50, with 82% of surveyed patients diagnosed before that age. An overwhelming 93% of HCPs believe current CRC treatments are insufficient. The survey highlighted that 61% of patients expressed interest in non-chemotherapy treatments, including immunotherapy, while 37% of HCPs identified immunotherapy as the most promising advancement in CRC treatment.
The study, conducted in partnership with the Colorectal Cancer Alliance and Fight Colorectal Cancer, emphasizes patients' prioritization of quality of life, with one-third citing minimal life impact as a top treatment priority. Most patients reported chemotherapy and radiation side effects as their most challenging aspect of treatment.
Agenus (NASDAQ: AGEN) has reported its Q4 and full-year 2024 financial results, highlighting significant operational improvements and cost reductions. The company achieved a Q4 2024 operational cash burn of $28.7 million and aims to reduce annual burn to approximately $50 million by mid-2025.
The company's botensilimab/balstilimab (BOT/BAL) program demonstrated promising clinical outcomes in resistant tumor types, particularly in colorectal cancer treatment. Data presented at ASCO-GI 2025 showed meaningful, durable responses across neoadjuvant and later lines of CRC treatment.
Financial highlights include:
- Year-end 2024 cash balance of $40.4 million (down from $76.1 million in 2023)
- 2024 revenue of $103.5 million
- Net loss of $232.3 million ($10.59 per share)
- Q4 revenue of $26.8 million with net loss of $46.8 million ($2.04 per share)
Agenus Inc. (NASDAQ: AGEN) has presented significant immuno-oncology data across multiple medical conferences and publications in 2024-2025, highlighting advances in cancer immunotherapy. The company's key antibody candidates, botensilimab (BOT) and balstilimab (BAL), have been evaluated in approximately 1,100 patients across 60+ centers worldwide.
The BOT/BAL combination has shown clinical responses across nine tumor types, including traditionally 'cold' tumors. Notable results include:
- High major pathological response rates in colorectal cancer (CRC) through the NEST and UNICORN trials
- 19% response rate in microsatellite stable (MSS) metastatic CRC patients with no liver metastases
- 71% objective response rate in combination with FOLFOX chemotherapy and bevacizumab in MSS metastatic CRC
- 19.2% overall response rate in sarcoma patients with 69% 12-month survival rate
Agenus (Nasdaq: AGEN), an immuno-oncology company, has announced its participation in the B. Riley Securities Precision Oncology & Radiopharma Investor Conference in New York. The company's Chief Commercial Officer, Robin Taylor, Ph.D., will join a panel discussion focused on 'What It Takes to Move the Needle in Improving Responses in Colorectal Cancer.' The event is scheduled for February 28th, 2025, from 1:00-2:00 p.m. ET. This in-person conference requires interested attendees to contact B. Riley for participation details.
Agenus Inc. (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, has announced it will release its fourth quarter and full year 2024 financial results before market opening on Tuesday, March 11th.
Following the release, Agenus executives will host a conference call and webcast at 8:30 a.m. ET to discuss the results and provide a corporate update. Interested parties can register to access the dial-in numbers with Conference ID: 73242.
A live webcast and replay of the conference call will be available on the company's investor relations website and through the provided event link.
Agenus (NASDAQ: AGEN) presented new data at the AACR IO Annual Meeting regarding their Phase 2 study combining botensilimab (BOT) and balstilimab (BAL) with MiNK Therapeutics' agenT-797 in refractory gastric cancer patients.
The key findings demonstrate that adding agenT-797 (an allogeneic invariant natural killer T cell therapy) to BOT/BAL treatment resulted in:
- Robust immune activation with elevated interferon-gamma levels
- Increased tumor-infiltrating lymphocytes
- Enhanced peripheral memory T-cell activation
- Potential for improved outcomes when administered before standard chemotherapy
The research suggests this combination therapy could effectively transform immunologically 'cold' tumors into 'hot' immune inflamed tumors, potentially offering new treatment options for late-line gastric cancer patients, including those who are PD-1 refractory.
Agenus (NASDAQ: AGEN) announced two upcoming presentations featuring BOT/BAL at the AACR IO Annual Meeting in Los Angeles (February 23-26). The first presentation will showcase interim data from a Phase 2 study combining botensilimab and balstilimab (BOT/BAL) with MiNK Therapeutics' iNKT cell therapy (AgenT-797) in refractory gastric cancer patients.
The second presentation will be a Trial-in-Progress poster highlighting data from an ongoing Phase 1/2 study of BOT/BAL in first-line MSS colorectal cancer. The presentations are scheduled for February 24th and 25th, covering biomarker analysis and treatment optimization strategies.
Agenus (NASDAQ: AGEN) has announced two upcoming presentations featuring BOT/BAL at the AACR IO Annual Meeting in Los Angeles from February 23-26. The first presentation will showcase interim data from a Phase 2 study combining botensilimab and balstilimab (BOT/BAL) with MiNK Therapeutics' iNKT cell therapy, AgenT-797, in patients with refractory gastric cancer.
The second presentation, a Trial-in-Progress poster, will focus on data from an ongoing Phase 1/2 study of BOT/BAL in first-line MSS colorectal cancer. The presentations are scheduled for Monday, February 24th, with the poster session running from 1:45-4:45 p.m. PST and the biomarker analysis presentation from 1:39-1:45 p.m. PST.
